Breaking News, Collaborations & Alliances

AbbVie, OSE Partner on mAbs for Chronic Inflammation

OSE to receive an $48 million upfront and is eligible to receive up to an additional $665 million in milestones.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AbbVie Inc. and OSE Immunotherapeutics, a clinical-stage immunotherapy company, entered a strategic partnership to develop OSE-230, a monoclonal antibody designed to resolve chronic and severe inflammation, currently in preclinical development.   OSE-230 is a first-in-class monoclonal antibody designed to activate ChemR23, a G-Protein Coupled Receptor (GPCR) target. Activation of ChemR23 may offer a novel mechanism for the resolution of chronic inflammation, modulating functions of both macrop...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters